Inhibrx presents Phase 2/3 HexAgon-HN study of ordastobart plus pembrolizumab at ESMO 2026

By Public Technologies
  • Inhibrx outlined upcoming conference presentations that will disclose new reads from mid- to late-stage oncology studies.
  • Primary analysis from the Phase 2 portion of HexAgon-HN will be presented Oct. 25, 2026 at ESMO in Madrid.
  • Secondary efficacy outcomes from the Phase 2 ChonDRAgon study in conventional chondrosarcoma are slated for Oct. 29, 2026 at MSTS.
  • Updated subgroup findings and progression-free survival from ChonDRAgon will be presented Nov. 20, 2026 at CTOS in Seoul.
  • Early clinical results from an INBRX-109 combination study in Ewing sarcoma are scheduled for a Nov. 19, 2026 poster at CTOS.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibrx Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA71319) on October 13, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk